LifeStance Health Group, Inc. (LFST)
SuperavaliadaFundamental
58
Preço
$12.03
Capitalização de Mercado
$4.57B
Parte 1 · Quanto vale a empresa
Visão Geral
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 19 de setembro de 2026 with claude-haiku-4-5 — shared with all users
Its behavioral health division has been adding outpatient mental-health locations across the US, competing market by market with LifeStance for the same commercially insured patients.
A privately held multi-state outpatient psychiatry and therapy group with 80+ clinics plus telehealth, competing for the same insured US patients and the same clinicians as LifeStance's hybrid clinic model.
A private national psychiatry practice in network with more than 60 US insurers, competing directly for the insurance-covered psychiatry and medication-management visits that are LifeStance's core revenue.
Offers insurance-covered virtual therapy and psychiatry to US consumers and employers, competing for the same outpatient mental-health visits that LifeStance delivers by telehealth.
A private platform that puts independent US therapists and psychiatrists in network with commercial payors, competing with LifeStance both for patients looking for an in-network clinician and for the clinicians themselves.
Through BetterHelp it is the largest virtual therapy brand in the US and is moving from cash-pay to insurance coverage, meeting LifeStance on the same outpatient therapy demand.
Balanço & Liquidez
Receita
$1.58B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$51M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$110M
Capital Próprio Total
$1.52B
Passivo Total
$683M
Rácio de Liquidez
1.38
Cobertura de Juros
7.75
Dívida/EBITDA
7.21
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$8.76
Preço Atual
$12.03
Margem de Segurança
-37.4%
Intervalo de Valor Justo
$5.69 - $11.82
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
92.54
ROE
0.6%
Rácio P/B
3.11
P/FCF
26.43
Margem Bruta
-
ROIC
3.3%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
3.3%
WACC
11.1%
ROIC − WACC
-7.8 pp
O ROIC está abaixo do custo do capital — a empresa está a destruir valor a cada dólar investido.
Critérios de Análise Fundamental
Aprovado (13)
- EPS shows upward trend
- P/FCF 26.43
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Return on Tangible Assets
- Revenue Growth 5Y 30.4%
- Analyst Consensus 78% Buy
- Earnings Surprise avg 621.9%
- Earnings Quality (OCF/NI) 4.31
- Net Margin Trend 3.2% vs -1.2%
- Piotroski F-Score 7/9
Reprovado (11)
- Price CAGR 4.88%
- ROIC 3.2%
- P/B Ratio 3.11
- Operating Margin 4.9%
- CapEx intensity
- Debt/EBITDA
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.4%
- Share Dilution 26.2%
Indisponível (3)
- Gross Margin NaN%
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Saúde financeira sólida
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A emitir novas ações, diluindo a participação
Participações institucionais
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Kenneth Alan Burdick J.D. | Executive Chairman | 66 |
| Mr. David Patrick Bourdon | CEO & Director | 56 |
| Mr. Ryan Bruce McGroarty | CFO & Treasurer | 52 |
| Mr. Vukasin Paunovich | Chief Technology Officer | 53 |
| Mr. Ryan Pardo J.D. | Chief Legal Officer & Secretary | 48 |
| Ms. Ann Varanakis | Chief People Officer | 47 |
| Ms. Lisa Keise Miller | Chief Operating Officer & Principal Operating Officer | 51 |
| Ms. Monica Prokocki | Vice President of Investor Relations | - |
| Brooke Matthews | Director of Public Relations | - |
| Mr. Richard Hall | Chief Shared Services Officer | - |
Risco de Auditoria
10
Risco do Conselho
10
Risco de Remuneração
7
Risco dos Direitos dos Acionistas
8
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Documentos
- Ver documento
Relatório anual (10-K)
Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.
Arquivado em 2026-02-25
- Ver documento
Relatório trimestral (10-Q)
Uma atualização sobre o desempenho financeiro dos últimos três meses.
Arquivado em 2026-08-06
- Ver documento
Relatório de fato relevante (8-K)
Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.
Arquivado em 2026-09-11
via SEC EDGAR
Histórico de Resultados
via SEC EDGAR
Latest News
Recent headlines for LFST, sourced from Markets Gazette.
- 2/25/2026NEUTRALLifeStance (LFST) Q4 2025 Earnings Call Transcript
The transcript for LifeStance Health Group, Inc.'s (LFST) Q4 2025 earnings call is now available. Investors and analysts have been keenly awaiting this document to gain in-depth insights into the company's financial performance for the period. While the specific content has not been disclosed in this announcement, the release of the transcript is a crucial event for market transparency. Market participants will now focus on analyzing management's statements, future projections, and responses to analyst questions to assess LifeStance's operational health and growth prospects. The market's reaction will hinge on the key metrics presented and the guidance provided.
via Markets Gazette